What is the evidence supporting the use of rituximab in crescentic IgA nephropathy?
Evidence for rituximab in crescentic IgA nephropathy is limited but includes observations of proteinuria reduction and potential relapse risk reduction when combined with corticosteroids compared to steroid monotherapy.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.5281/zenodo.24299560
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00